Special Issue

Effects of Drugs on Ion Channels

Message from the Guest Editors

You are invited to submit original articles that demonstrate the effects of new molecules on ion channels or describe the mechanism of action of known molecules (small molecule compounds as well as peptides) that have vet to be clarified. We also welcome submissions of review articles that summarize the current state of knowledge and help researchers to navigate this field. Many ion channel mutations have been associated with diseases such as LQT syndrome, Brugada syndrome, epilepsy, etc., which are called channelopathies. For this reason, one of the most important ultimate goals of ion channel modulator research is to find molecules that may be potential drug candidates, either acting as an inhibitor or as an activator. On the other hand, understanding the factors that regulate gating transitions of ion channels may aid the design of more efficacious drugs with statedependent binding. Consequently, studies of the drugion channel interactions in channels that display inactivation are also necessary and relevant.

Guest Editors

Dr. Ferenc Papp

Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Egyetem ter 1, H-4032 Debrecen, Hungary

Dr. Tibor Gabor Szántó

Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Egyetem ter 1, H-4032 Debrecen, Hungary

Deadline for manuscript submissions

closed (30 December 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/113259

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

